Risk Factors And Surgical Outcomes Of Strabismus Reoperation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorAssiut University

About this trial

Horizontal strabismus, commonly known as inward or outward deviation of the eyes, is a frequent eye condition that may require surgical correction. Although the first surgery is often successful, some patients develop residual or recurrent eye misalignment and require a second operation (reoperation).

This study aims to identify the clinical and surgical factors that may increase the risk of undercorrection, overcorrection, or recurrence after the first surgery. It also evaluates the outcomes and success rate of repeat surgery in patients with horizontal strabismus.

Patients undergoing reoperation will receive a complete ophthalmological examination before surgery. The surgical plan will be individualized based on previous surgical history and current eye findings. All procedures will be performed under general anesthesia by the same surgeon. Participants will be followed for three months after surgery to assess eye alignment, movement, and possible complications.

The results of this study may help improve surgical planning and predict which patients are at higher risk of requiring additional surgery in the future.

Eligibility criteria

Qualifiers

Patients diagnosed with horizontal strabismus (esotropia or exotropia).

Patients undergoing repeat surgery for correction of residual, recurrent, undercorrected, or overcorrected horizontal strabismus.

Availability of sufficient medical records documenting previous strabismus surgery.

Ability to attend scheduled postoperative follow-up visits.

Disqualifiers

Combined vertical and horizontal strabismus.

Paralytic strabismus.

Restrictive strabismus.

Strabismus associated with neurological or syndromic conditions.

Trial design

Treatments tested in this trial

  • Horizontal Strabismus Reoperation

Treatment groups

62 Participants
are divided into 1 treatment group

Sponsors and collaborators